Acute Coronary Syndrome Clinical Trials

Find Acute Coronary Syndrome Clinical Trials Near You

Pre Hospital Triage of Patients at Intermediate and High Risk for ACS: ARTICA-2 Trial

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

RESEARCH QUESTION: Is a treatment strategy that includes direct referral to a PCI center for intermediate to high-risk patients with non-ST elevation acute coronary syndrome (NSTE-ACS), both cost-effective and non-inferior for major adverse cardiac events (MACE)? HYPOTHESIS: Prehospital triage with the modified \[History-ECG-Age-Risk factors\] (HEAR) score and a high sensitivity (hs) point-of-care troponin (POCT) leads to a faster diagnosis of ACS, faster time to coronary angiography (CAG) and/or treatment with PCI, shorter length of stay, quicker availability of ambulances and more satisfaction and quality of life of patients. STUDY DESIGN: Randomized clinical trial. STUDY POPULATION: Patients ≥18 years with an intermediate to high risk for NSTE -ACS (defined as a modified HEAR score ≥ 4) INTERVENTION: applying modified HEAR score and hs POCT to identify patients for direct rule out (very low risk), transfer to the nearest hospital for rapid rule-out and/or fast-track diagnosis by CT coronary imaging (intermediate risk) or direct referral to a PCI center for CAG (high risk). USUAL CARE/COMPARISON: Assessment of ACS at the nearest hospital. In case PCI is scheduled: transfer to nearest PCI center. OUTCOME MEASURES: primary endpoints: healthcare costs and non-inferiority for MACE (all cause death, confirmed ACS, re ACS, and unplanned PCI or CABG) at 30 days. Secondary: MACE after rule out ACS at 30 days, Quality of life (EQ5D5L) and cost-effectiveness at 12 months. SAMPLE SIZE: 1048 patients. COST-EFFECTIVENESS ANALYSIS / BIA: It is expected that the intervention group will reduce healthcare costs and potentially improve health-related quality of life in this target population. Cost-effectiveness will be expressed as cost per QALY gained. We assume a large potential saving more than € 37 million if 100% implemented. TIME SCHEDULE: 48 months; 36 month inclusion, follow-up 12 months

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• All out-of-hospital patients with chest pain or symptoms suggestive of ACS with an indication for transfer to the (cardiac) emergency department to evaluate and rule out ACS

• Modified HEAR(T) score ≥ 4

• The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Locations
Other Locations
Netherlands
RAV Brabant midden-west-noord: post Haps
RECRUITING
Haps
Radboudumc Nijmegen, The Netherlands
RECRUITING
Nijmegen
Veiligheidsregio Gelderland-Zuid
NOT_YET_RECRUITING
Nijmegen
Contact Information
Primary
Cyril Camaro, MD
articastudie.cardio@radboudumc.nl
+31243616785
Backup
Cyril Camaro
cyril.camaro@radboudumc.nl
+31243616785
Time Frame
Start Date: 2026-09-04
Estimated Completion Date: 2030-02-01
Participants
Target number of participants: 1048
Treatments
Active_comparator: Intervention group
Integrating the HEAR score and hs POC troponin into pre hospital triage decision-making:
No_intervention: Standard care group
intermediate and high risk patients referred to the nearest hospital for standard care. The ACS rule-out protocol follows the 2023 Guidelines of the European Society of Cardiology (ESC). In confirmed cases of ACS, patients should be scheduled for invasive coronary angiography within the recommended time window as outlined by the ESC guidelines
Related Therapeutic Areas
Sponsors
Leads: Cyril Camaro
Collaborators: Ambulance services Veiligheidsregio Gelderland-Zuid, Maas Hospital Pantein, RAV Brabant MWN, Canisius-Wilhelmina Hospital, Slingeland Hospital, Rijnstate Hospital

This content was sourced from clinicaltrials.gov